Syner-G to provide GMP manufacturing oversight and integrated development support as BETR-001 progresses toward IND submission and Phase 1 clinical studies.
Syner-G is pleased to announce its partnership with BetterLife Pharma to support the advancement of BETR-001 as it moves toward Investigational New Drug (IND) submission and Phase 1 clinical development. As part of this collaboration, Syner-G will oversee GMP manufacturing activities and provide integrated development support to help prepare the program for its next stage of growth.
BETR-001 (2-bromo-LSD) is being developed for chronic cluster headache and chronic migraine conditions. The program is currently completing final IND-enabling studies, with plans to initiate Phase 1 clinical trials following an anticipated IND submission in 2027.
Read the full announcement from BetterLife Pharma:
